Beam stock launched a year-high Tuesday as enthusiasm grows for its next-generation form of gene editing, a rival to CRISPR.

The post Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr’s New Gene-Editing Drug appeared first on Investor’s Business Daily.